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Scott L DuVall, Kristine Lynch, Thomas Falconer, Kees van Bochove, Cynthia Sung, Michael E Matheny, Christophe G Lambert, Fredrik Nyberg, 
Thamir M Alshammari, Andrew E Williams, Rae Woong Park, James Weaver, Anthony G Sena, Martijn J Schuemie, Peter R Rijnbeek, 
Ross D Williams, Jennifer C E Lane, Albert Prats-Uribe, Lin Zhang, Carlos Areia, Harlan M Krumholz, Daniel Prieto-Alhambra, Patrick B Ryan, 
George Hripcsak, Marc A Suchard
Summary
Background Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been 
postulated to affect susceptibility to COVID-19. Observational studies so far have lacked rigorous ascertainment 
adjustment and international generalisability. We aimed to determine whether use of ACEIs or ARBs is associated 
with an increased susceptibility to COVID-19 in patients with hypertension.
Methods In this international, open science, cohort analysis, we used electronic health records from Spain (Information 
Systems for Research in Primary Care [SIDIAP]) and the USA (Columbia University Irving Medical Center data 
warehouse [CUIMC] and Department of Veterans Affairs Observational Medical Outcomes Partnership [VA-OMOP]) to 
identify patients aged 18 years or older with at least one prescription for ACEIs and ARBs (target cohort) or calcium 
channel blockers (CCBs) and thiazide or thiazide-like diuretics (THZs; comparator cohort) between Nov 1, 2019, and 
Jan 31, 2020. Users were defined separately as receiving either monotherapy with these four drug classes, or monotherapy 
or combination therapy (combination use) with other antihypertensive medications. We assessed four outcomes: 
COVID-19 diagnosis; hospital admission with COVID-19; hospital admission with pneumonia; and hospital admission 
with pneumonia, acute respiratory distress syndrome, acute kidney injury, or sepsis. We built large-scale propensity 
score methods derived through a data-driven approach and negative control experiments across ten pairwise comparisons, 
with results meta-analysed to generate 1280 study effects. For each study effect, we did negative control outcome 
experiments using a possible 123 controls identified through a data-rich algorithm. This process used a set of predefined 
baseline patient characteristics to provide the most accurate prediction of treatment and balance among patient cohorts 
across characteristics. The study is registered with the EU Post-Authorisation Studies register, EUPAS35296.
Findings Among 1 355 349 antihypertensive users (363 785 ACEI or ARB monotherapy users, 248 915 CCB or THZ 
monotherapy users, 711 799 ACEI or ARB combination users, and 473 076 CCB or THZ combination users) included 
in analyses, no association was observed between COVID-19 diagnosis and exposure to ACEI or ARB monotherapy 
versus CCB or THZ monotherapy (calibrated hazard ratio [HR] 0·98, 95% CI 0·84–1·14) or combination use 
exposure (1·01, 0·90–1·15). ACEIs alone similarly showed no relative risk difference when compared with CCB or 
THZ monotherapy (HR 0·91, 95% CI 0·68–1·21; with heterogeneity of >40%) or combination use (0·95, 0·83–1·07). 
Directly comparing ACEIs with ARBs demonstrated a moderately lower risk with ACEIs, which was significant with 
combination use (HR 0·88, 95% CI 0·79–0·99) and non-significant for monotherapy (0·85, 0·69–1·05). We observed 
no significant difference between drug classes for risk of hospital admission with COVID-19, hospital admission with 
pneumonia, or hospital admission with pneumonia, acute respiratory distress syndrome, acute kidney injury, or 
sepsis across all comparisons.
Interpretation No clinically significant increased risk of COVID-19 diagnosis or hospital admission-related outcomes 
associated with ACEI or ARB use was observed, suggesting users should not discontinue or change their treatment to 
decrease their risk of COVID-19.
Funding Wellcome Trust, UK National Institute for Health Research, US National Institutes of Health, US Department 
of Veterans Affairs, Janssen Research & Development, IQVIA, South Korean Ministry of Health and Welfare Republic, 
Australian National Health and Medical Research Council, and European Health Data and Evidence Network.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
People with cardiovascular diseases and hypertension are 
more likely to develop severe complications from 
COVID-19, which is caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2), including hosp ital 
admission and death.1–3 Speculatively, angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin 
receptor blockers (ARBs), both of which block the renin–
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angio tensin system (RAS), might affect people’s 
susceptibility to COVID-19 and worsen its severity. Driving 
this hypothesis is the mechanism by which SARS-CoV-2 
enters human cells: by binding to the membrane-bound 
aminopeptidase angiotensin-converting enzyme 2 
(ACE2), the expression of which might be altered by 
chronic exposure to RAS therapy.4–13 Speculation about the 
effects of RAS therapy on susceptibility to and severity of 
COVID-19 has generated substantial public health 
concerns, resulting in the release of statements from 
health regulatory agencies and clinical societies advocating 
that, in the absence of direct evidence of harm with 
COVID-19, these medicines should not be discontinued.14,15 
However, inconsistencies in recommen dations have 
emerged, with suggestions that users of these medicines 
should be monitored closely. Unlike clinical trials that are 
being proposed to investigate the withdrawal of ACEIs 
and ARBs among symptomatic patients with COVID-19, 
it is less likely that large-scale, population-based trials 
assessing susceptibility to COVID-19 among users of RAS 
therapy will be done in a timely manner.16,17 Withholding 
these medicines, however, might result in worse 
cardiovascular outcomes, with some studies reporting an 
increased risk of myocardial injury resulting from illness 
with COVID-19.1
Several studies have emerged examining this 
conundrum. Although informative, they have had small 
sample sizes, limited confounder adjustment, used 
hetero geneous comparisons, or had methodological 
limitations, including immortal time bias and collider 
bias.18–21 For example, comparing the risk of COVID-19 
among users of ACEIs or ARBs with an unexposed control 
population can result in recruitment of non-comparable 
participants, confounding by indication, and the absence 
of a clear index date for when follow-up should start, all of 
which can induce bias. Reliable evidence should also be 
replicable, generalisable, and robust. To draw strong 
conclusions from observational studies, it is essential that 
consistent findings are produced from transparent, well 
designed analyses across multiple populations and data 
capture processes to ensure that any associations are not 
due to systematic error or applicable only in narrow 
contexts. We aimed to determine whether exposure to 
ACEIs or ARBs is associated with an increased 
susceptibility to COVID-19 among patients with 
hypertension.
Methods
Study design
We did a systematic and comprehensive federated active-
comparator cohort study facilitated by a common data 
model. The protocol for the International Covid-ACE 
Receptor Inhibition Utilization and Safety (ICARIUS) 
studies was drafted and carried out by an international 
team of clinical, academic, government, and industry 
stakeholders through the Observational Health Data 
Sciences and Informatics (OHDSI) network.22
Data sources
We identified patients in routinely collected electronic 
health records (EHRs) and claims data from the USA 
and Spain. All data sources had been mapped to the 
Observational Medical Outcomes Partnership (OMOP) 
common data model (version 5).23 Two particular benefits 
of this standardisation are that contributing centres can 
participate in distributed network analyses without 
needing to share patient-level information and that data 
provenance can be ensured while applying a common 
Research in context
Evidence before this study
We systematically searched PubMed, Embase, clinical trial 
registries, and preprint servers for research articles published 
from inception until March 27, 2020. No language restriction 
was applied. We found no investigations of the real-world 
safety of first-line antihypertensive medications involving 
COVID-19 diagnoses. Studies examining the association 
between renin–angiotensin system inhibitor use and COVID-19 
susceptibility have since been published that report no 
COVID-19 risk or a lower risk associated with use of 
angiotensin-converting enzyme inhibitors (ACEIs) and 
angiotensin receptor blockers (ARBs). However, these studies 
have small sample sizes, limited confounder adjustment, or 
methodological limitations such as immortal time bias and 
collider bias. We identified one small study directly comparing 
the effects of ACEI versus ARB use among symptomatic 
patients with COVID-19 that showed no difference in patient 
outcomes.
Added value of this study
This study comprehensively evaluates the safety of ACEIs and 
ARBs in COVID-19 by examining a large number of different 
comparisons using state-of-the-art methods to control for 
residual confounding and bias across a distributed network. 
Our study shows similar results across three databases from 
two countries. ACEI and ARB use does not confer increased risk 
of: COVID-19 diagnosis; hospital admission with COVID-19; 
hospital admission with pneumonia; or hospital admission with 
pneumonia, acute respiratory distress syndrome, acute kidney 
injury, or sepsis compared with people taking calcium channel 
blockers and thiazide or thiazide-like diuretics.
Implications of all the available evidence
Use of ACEIs and ARBs does not affect COVID-19 susceptibility 
risk, and these results are in keeping with medicines regulatory 
and clinical society recommendations that patients should not 
alter their treatment with these medicines to reduce their 
COVID-19 risk.
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analytical code across all data sources in a consistent 
manner. The data sources included the Columbia 
University Irving Medical Center (New York, NY, USA) 
data warehouse (CUIMC), the Information Systems for 
Research in Primary Care (SIDIAP) database, and the US 
Department of Veterans Affairs OMOP (VA-OMOP) 
database. CUIMC EHRs contain data, including clinical 
diagnoses, prescriptions, laboratory tests, demographics, 
and COVID-19 tests and diagnosis, from approximately 
6 million cumulative patients from the New York-
Presbyterian Hospital and Columbia University Irving 
Medical Center in the USA.24 SIDIAP covers 
approximately 80% of the population of Catalonia 
(Spain), with approximately 6 million patients, and 
contains data collected since 2006 from general practice 
EHRs linked to hospital admissions, with information 
on diagnoses, prescriptions, laboratory tests, and lifestyle 
and sociodemographics, and the central database of 
RT-PCR COVID-19 tests.25 VA-OMOP covers 
approximately 12 million patients from 170 medical 
centres across the USA and includes administrative, 
clinical, laboratory, and pharmacy data repositories that 
are linked using unique patient identifiers.26
All data partners received institution review board 
approval or waiver in accordance with their institutional 
governance guidelines. Use of SIDIAP was approved by 
the Clinical Research Ethics Committee of the Institut 
Universitari d’Investigació en Atenció Primària Jordi Gol 
(Barcelona, Spain; project code 20/070-PCV). Use of 
VA-OMOP was reviewed by the US Department of 
Veterans Affairs Central Institutional Review Board and 
was determined to meet the criteria for exemption under 
Exemption Category 4(3) and approved the request for 
Waiver of HIPAA Authorization. Use of CUIMC was 
approved by the Columbia University Institutional 
Review Board as an OHDSI network study (AAAO7805).
Cohort eligibility, study period, and follow-up
Each cohort consisted of adults aged 18 years or older 
who received at least one outpatient prescription for an 
ACEI, ARB, calcium channel blocker (CCB), or thiazide 
or thiazide-like diuretic (THZ) between Nov 1, 2019, and 
Jan 31, 2020. The index date (ie, start of cohort follow-up) 
was set as the date of the last prescription in this time 
window (figure 1). We required patients to be observable 
in their data source for at least 180 days before the index 
date and have a diagnostic code for hypertension at any 
point before or including the index date. Cohort exit was 
the earliest of the occurrence of an outcome; the end of 
exposure, death, loss or deregistration from the database; 
or date of last data collection.
Exposures
The exposures of interest were four first-line anti-
hypertensive drug classes: ACEIs, ARBs, CCBs, or THZs. 
Users were defined separately as receiving either 
Figure 1: ICARIUS susceptibility study design
We highlight eligibility criteria, exposure definitions, adjustment strategies, index date specification (day 0; horizontal black arrow), and outcome definitions and 
time at risk. Exposure involves prescriptions to drugs with RxNorm ingredients that map to the first-line antihypertensive drug classes: ACEIs, ARBs, CCBs, and THZs. 
ACEI=angiotensin-converting enzyme inhibitor. ARB=angiotensin receptor blocker. CCB=calcium channel blocker. CUIMC=Columbia University Irving Medical 
Center data warehouse. ICARIUS=International Covid-19 ACE Receptor Inhibition Utilization and Safety. SIDIAP=Information Systems for Research in Primary 
Care. THZ=thiazide or thiazide-like diuretic. VA-OMOP=US Department of Veterans Affairs Observational Medical Outcomes Partnership. *For monotherapy 
analysis only; other antihypertensive therapy included rate-limiting CCBs, diuretics, and β blockers. †Day 0 is the most recent observed prescription for target or 
drug comparator between Nov 1, 2019, and Jan 31, 2020.
Outcomes
Censoring events: treatment discontinuation, data 
disenrolment, death or outcome of interest
1) COVID-19 diagnosis
2) Hospital admission with COVID-19
3) Hospital admission with pneumonia
4) Hospital admission with pneumonia, acute
respiratory distress syndrome, acute kidney 
injury, or sepsis
Eligibility
Exposure (ACEIs, ARBs, CCBs, and THZs)
Adjustment (propensity score matching or stratification) 
Covariate assessment: conditions, drugs, procedures, measurements, devices, and observations
Enrolment in CUIMC, SIDIAP, or VA-OMOP
At least 180 days before day 0
No observed history of the outcome
Any time before day 0
At least one hypertension diagnosis
Any time before day 0
No other antihypertensive therapy prescription*
–180 to day 0
Any time before day 0
–180 to day 0
–30 to day 0
Day –180 Day –30
Study timeline
Day 0†
Follow-up to end of data availability
For the ICARIUS protocol see 
https://github.com/ohdsi-
studies/Covid19Icarius
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(1) monotherapy or (2) monotherapy or combination 
therapy (combination use) with other antihypertensive 
medications. Our primary comparison examined 
outpatient exposure to RAS blockers (ACEI or ARBs) 
with exposure to CCBs or THZs (included as active 
comparators). Further investigation compared class 
exposure to ACEIs with exposure to ARBs separately, and 
individual classes to various active comparators, leading 
to ten different target–comparator pairings for mono-
therapy and combination use each, as listed in the 
appendix (pp 2–13). For patients on monotherapy, we 
required the absence of any other antihypertensive 
treatment between –180 days and 0 days before the index 
date. We defined continuous drug exposures from the 
start of follow-up by grouping sequential prescriptions 
that had at most a 30-day gap between prescriptions, and 
defined the end of exposure as the end of the last 
prescription’s drug supply in such a sequence.
Outcomes
We investigated four COVID-19-related outcomes: 
COVID-19 diagnosis; hospital admission with COVID-19; 
hospital admission with pneumonia; and hospital 
admission with pneumonia, acute respiratory distress 
syn drome, acute kidney injury, or sepsis. Positive 
COVID-19 PCR test results or SNOMED diagnostic 
codes defined COVID-19 status. COVID-19 antibody tests 
were not available when we did the study. The full details 
of the participant cohorts and outcome definitions used 
can be found in the protocol.
Statistical analysis
We undertook this study using all patients who met the 
eligibility criteria within each database. Therefore, we did 
not calculate the sample size a priori; instead, we provide 
a minimum detectable rate ratio (MDRR) for each target–
comparator–outcome triplet across each data source.27
To adjust for potential measured confounding and to 
improve the balance between comparison cohorts, we built 
large-scale propensity score models for each comparison 
and data source using a consistent data-driven process 
through regularised regression.27,28 This process used a 
large set of predefined baseline patient characteristics 
(including age, sex, race [US data], and other demographics) 
and previous conditions, drug exposures, procedures, and 
health service use behaviours to provide the most accurate 
prediction of treatment and balance patient cohorts across 
many characteristics. For computational efficiency, we 
excluded all features that occurred in fewer than 0·1% of 
patients within the target and comparator cohorts before 
propensity score model fitting.
In separate analyses, we stratified patients into 
five propensity score quintiles or variable-ratio matched 
patients by propensity, and used Cox proportional hazards 
models to estimate hazard ratios (HRs) between 
alternative target and comparator treatments for the risk 
of each outcome in each data source. The regression 
conditioned on the propensity score strata or matching 
units, with treat ment allocation as the sole explanatory 
variable. We aggregated HR estimates across data sources 
to produce meta-analytic estimates using a random-effects 
meta-analysis.29 We only included estimates that passed 
propensity score diagnostics in the main meta-analysis, 
with meta-analytic estimates based on all data sources 
provided as a sensitivity analysis. For both monotherapy 
and combination use of the ACEI, ARB, CCB, THZ, ACEI 
or ARB, and CCB or THZ class groups (ten pairwise 
comparisons) to study four outcomes in three data sources 
(plus one meta-analysis) using two propensity score-
adjustment approaches, we generated 1280 study effects.
Residual study bias from unmeasured and systematic 
sources often remains in observational studies even after 
controlling for measured confounding through propen-
sity score adjustment.30,31 For each study effect, we did 
negative control outcome experiments, for which the 
null hypothesis of no effect is believed to be true, using a 
possible 123 controls identified through a data-rich 
algorithm and validated in a previous antihypertensive 
comparative study.32,33 Using the empirical null 
distributions from these experiments, we calibrated each 
study effect HR estimate, its 95% CI, and the p value to 
reject the null hypothesis of no differential effect.34 We 
declared an HR as significantly different from no effect 
when its calibrated p value was less than 0·05 without 
correcting for multiple testing.
These study diagnostics were presented to clinicians and 
epidemiologists who were masked to the HRs generated by 
the models for evaluation to provide an unbiased 
assessment of their validity. The suite of diagnostics 
included the MDRR, the preference score (a transformation 
of the propensity score that adjusts for prevalence 
differences between populations) distributions to evaluate 
empirical equipoise and popu lation generalisability,35 
extensive patient characteristics to evaluate cohort balance 
before and after adjustment using the propensity score, 
negative control calibration plots to assess residual bias, 
and Kaplan-Meier plots to examine HR proportionality 
assumptions. We defined target and comparator cohorts to 
stand in empirical equipoise if the majority of patients in 
both carried preference scores between 0·3 and 0·7 and to 
achieve sufficient balance if all after-adjustment baseline 
characteristics returned an absolute standardised mean 
differences of less than 0·1.36 Heterogeneity following 
meta-analysis was defined by an I² value of more than 40%.
We did this study using the open-source OHDSI 
CohortMethod R package with large-scale analytics made 
possible through the Cyclops R package.32 The prespecified 
ICARIUS protocol and start-to-finish open and executable 
source code are available online. To promote transparency 
and facilitate sharing and exploration of the complete 
result set, an interactive web application provides study 
diagnostics and results for all study effects.
The study is registered with the EU Post-Authorisation 
Studies register, EUPAS35296.
For the OHDSI CohortMethod 
R package see https://ohdsi.
github.io/CohortMethod/
For the prespecified ICARIUS 
protocol and start-to-finish 
open and executable source 
code see https://github.com/
ohdsi-studies/Covid19Icarius
For the interactive web 
application see https://data.
ohdsi.org/IcariusSusceptibility
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Role of the funding source
The funders of the study had no role in study design, 
study execution, data collection, data interpretation, 
writing of the report, or the decision to submit for 
publication, and all authors share responsibility for the 
decision to submit this work for publication. This was a 
federated data analysis, and no single author had access 
to all of the underlying data. TD-S, SF-B, and MA had 
access to the data in SIDIAP; TF and GH had access to 
the data in CUIMC; and SLD and KL had access to the 
data in VA-OMOP. DRM, MMC, SCY, GH, and MAS had 
full access to all aggregate results.
Results
Among 1 355 349 patients included in the analysis, 
363 785 patients with hypertension who received ACEI or 
ARB monotherapy were compared with 248 915 patients 
who received CCB or THZ monotherapy, contributing 
121 213 person-years and 81 261 person-years of follow-
up, respectively. The overall incidence of COVID-19 
diagnosis was 5·6 per 1000 person-years among patients 
who received ACEI or ARB monotherapy compared with 
4·8 per 1000 person-years among those who received 
CCB or THZ monotherapy, although incidence rates 
varied by data source.
Corresponding patient cohort size and diagnosis 
incidence rates were 268 711 and 5·6 per 1000 person-
years for ACEI (alone) monotherapy users and 92 485 and 
5·1 per 1000 person-years for ARB (alone) monotherapy 
users. Cohorts for combination users (as monotherapy or 
combination therapy) were as large as 711 799 for ACEI or 
ARB users and 473 076 for CCB or THZ users.
The aggregated patient cohort size, follow-up duration, 
incidences of each COVID-19-related outcome, and 
MDRR for each drug comparison and database are 
shown in table 1. The appendix (pp 2–13) provides further 
cohort size and outcome event information for all 
ten pairwise cohort comparisons across all four 
outcomes.
Baseline characteristics of ACEI or ARB monotherapy 
users compared with CCB or THZ monotherapy users, 
before and after propensity score stratification, are shown 
in tables 2–4. There were baseline differences in sex, 
hyperlipidaemia, diabetes, renal impairment, heart 
failure, heart disease, atrial fibrillation, drugs for 
diabetes, lipid-modifying agents, antithrombotics, ant-
acids, opioids, and race that varied by data source. 
Further information on the population characteristics for 
each cohort comparison and design evaluated for each 
data source are shown in the appendix (pp 14–162), 
one for each of the 60 comparisons across data sources.
The number of baseline patient characteristics differed 
across comparison cohorts and data sources. The process 
generated more than 10 000 unique features in each data 
source; the number of characteristics present in at least 1% 
of patients in each comparison cohort ranged from 
2284 to 2473 in SIDIAP, 2657 to 3366 in VA-OMOP, and 
2694 to 3859 in CUIMC. After large-scale propensity score 
construction, followed by stratification or matching, 
standardised mean differences for all baseline charac-
teristics were less than 0·1 in SIDIAP and VA-OMOP for 
each drug comparison, apart from the comparison 
between combination users of ARBs and CCBs or THZs 
in VA-OMOP. Standardised mean differences for all 
baseline characteristics before and after propensity score 
adjustment for ACEI or ARB monotherapy users 
Patients Time, years Events MDRR
Target 
cohort
Comparator 
cohort
Target 
cohort
Comparator 
cohort
Target 
cohort
Comparator 
cohort
ACEIs or ARBs vs CCBs or THZs
Monotherapy
SIDIAP 37 796 14 003 10 239 3 780 500 184 1·27
VA-OMOP 320 450 229 063 110 380 76 856 145 183 1·37
CUIMC 5539 5849 594 625 28 24 2·18
Combination use
SIDIAP 45 239 19 007 12 264 5175 627 250 1·23
VA-OMOP 656 274 443 061 228 678 150 755 345 335 1·24
CUIMC 10 286 11 008 1128 1185 59 58 1·68
ACEIs vs CCBs or THZs
Monotherapy
SIDIAP 30 787 14 003 8293 3780 398 184 1·28
VA-OMOP 235 348 229 063 80 760 76 856 96 183 1·40
CUIMC 2576 5849 277 625 10 24 2·84
Combination use
SIDIAP 36 323 29 239 9803 7941 485 399 1·21
VA-OMOP 457 557 639 500 158 721 221 239 218 494 1·24
CUIMC 4811 16 302 511 1754 18 83 1·94
ARBs vs CCBs or THZs
Monotherapy
SIDIAP 6753 14 003 1815 3780 95 184 1·43
VA-OMOP 82 872 229 063 28 689 76 856 46 183 1·52
CUIMC 2860 5849 301 625 17 24 2·54
Combination use
SIDIAP 9194 39 427 2457 10 714 137 519 1·32
VA-OMOP 201 503 854 224 70 267 295 986 127 574 1·31
CUIMC 5669 14 271 629 1533 41 77 1·77
ACEIs vs ARBs
Monotherapy
SIDIAP 30 787 6753 8293 1815 398 95 1·39
VA-OMOP 235 348 82 872 80 760 28 689 96 46 1·71
CUIMC 2576 2860 277 301 10 17 2·94
 Combination use
SIDIAP 56 465 19 148 15 333 5176 758 283 1·22
VA-OMOP 865 931 395 156 303 491 140 071 441 282 1·25
CUIMC 7880 10 769 826 1179 39 66 1·74
ACEI=angiotensin-converting enzyme inhibitor. ARB=angiotensin receptor blocker. CCB=calcium channel blocker. 
CUIMC=Columbia University Irving Medical Center data warehouse. MDRR=minimum detectable risk ratio. 
SIDIAP=Information Systems for Research in Primary Care. THZ=thiazide or thiazide-like diuretic. VA-OMOP=US 
Department of Veterans Affairs Observational Medical Outcomes Partnership.
Table 1: Populations and COVID-19 diagnoses for ACEI, ARB, CCB, and THZ monotherapy and 
combination user cohorts
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Before stratification After stratification
Target SIDIAP 
cohort 
(n=37 796)
Comparator 
SIDIAP cohort 
(n=14 003)
Standardised 
mean 
difference
Target SIDIAP 
cohort 
(n=37 796)
Comparator 
SIDIAP cohort 
(n=14 003)
Standardised 
mean 
difference
Age group, years
<25 0·1% 0·1% 0·00 0·1% 0·1% –0·01
25–29 0·2% 0·2% 0·00 0·2% 0·2% –0·01
30–34 0·6% 0·6% 0·01 0·6% 0·6% 0·00
35–39 1·6% 1·0% 0·04 1·4% 1·3% 0·01
40–44 3·8% 2·3% 0·08 3·4% 3·3% 0·01
45–49 7·0% 5·0% 0·08 6·4% 6·5 0·00
50–54 10·4% 7·9% 0·09 9·6% 9·9% –0·01
55–59 12·5% 10·2% 0·07 11·8% 12·1% –0·01
60–64 13·7% 12·5% 0·03 13·4% 13·2% 0·00
65–69 13·4% 13·4% 0·00 13·5% 13·2% 0·01
70–74 12·9% 14·6% –0·05 13·4% 13·4% 0·00
75–79 9·8% 12·7% –0·09 10·7% 10·5% 0·01
80–84 6·8% 9·0% –0·08 7·4% 7·4% 0·00
85–89 4·7% 6·5% –0·08 5·2% 5·2% 0·00
90–94 2·1% 2·9% –0·06 2·3% 2·3% 0·00
≥95 0·5% 0·8% –0·04 0·5% 0·7% –0·02
Sex
Female 46·8% 53·0% –0·12 48·9% 47·8% 0·02
Male 53·2% 47·0% –0·12 51·1% 52·2% 0·02
Medical history: general
Acute respiratory disease 8·6% 8·4% 0·01 8·6% 8·5% 0·00
Attention deficit hyperactivity disorder 0·1% 0·1% 0 0·1% 0·1% 0·00
Chronic liver disease 1·5% 1·7% –0·02 1·6% 1·7% –0·01
Chronic obstructive lung disease 6·0% 7·0% –0·04 6·2% 6·3% 0·00
Crohn’s disease 0·2% 0·2% 0 0·2% 0·2% 0·01
Dementia 2·3% 2·7% –0·03 2·5% 2·3% 0·01
Depressive disorder 13·6% 14·8% –0·04 14·0% 13·7% 0·01
Diabetes 19·9% 22·8% –0·07 20·7% 20·4% 0·01
Gastro-oesophageal reflux disease 10·0% 11·5% –0·05 10·4% 10·4% 0·00
Gastrointestinal haemorrhage 0·7% 0·8% –0·01 0·7% 0·7% –0·01
HIV infection 0·5% 0·4% 0·02 0·5% 0·4% 0·01
Hyperlipidaemia 26·7% 27·9% –0·03 27·0% 26·9% 0·00
Hypertensive disorder 99·2% 99·3% –0·01 99·2% 99·3% –0·01
Lesion of liver 0·8% 1·0% –0·03 0·8% 0·9% –0·01
Obesity 34·6% 37·5% –0·06 35·5% 35·6% 0·00
Osteoarthritis 27·9% 33·2% –0·12 29·6% 28·9% 0·01
Pneumonia 0·7% 0·6% 0·01 0·7% 0·6% 0·02
Psoriasis 3·7% 3·7% 0·00 3·7% 3·7% 0·00
Renal impairment 8·1% 13·8% –0·18 9·4% 10·0% –0·02
Rheumatoid arthritis 0·4% 0·5% 0·00 0·5% 0·4% 0·01
Schizophrenia 0·5% 0·5% 0·00 0·5% 0·5% –0·01
Ulcerative colitis 0·4% 0·5% –0·01 0·4% 0·4% 0·00
Urinary tract infectious disease 4·9% 5·3% –0·02 5·1% 4·9% 0·01
Viral hepatitis C 1·2% 1·2% 0·00 1·2% 1·2% 0·00
Visual system disorder 36·5% 42·0% –0·11 38·1% 37·5% 0·01
Atrial fibrillation 3·8% 4·6% –0·04 4·1% 3·9% 0·01
Cerebrovascular disease 2·1% 2·4% –0·02 2·2% 2·0% 0·01
Coronary arteriosclerosis 0 0 0·01 0 0 0·01
(Table 2 continues next page)
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Before stratification After stratification
Target SIDIAP 
cohort 
(n=37 796)
Comparator 
SIDIAP cohort 
(n=14 003)
Standardised 
mean  
difference
Target SIDIAP 
cohort 
(n=37 796)
Comparator 
SIDIAP cohort 
(n=14 003)
Standardised 
mean  
difference
(Continued from previous page)
Heart disease 20·7% 24·9% –0·10 21·8% 21·8% 0·00
Heart failure 1·7% 2·1% –0·03 1·8% 1·7% 0·00
Ischaemic heart disease 3·9% 4·7% –0·04 4·1% 4·0% 0·01
Peripheral vascular disease 2·7% 4·3% –0·08 3·1% 3·2% –0·01
Pulmonary embolism 0·5% 0·6% –0·01 0·6% 0·5% 0·01
Venous thrombosis 1·0% 1·1% –0·01 1·1% 0·9% 0·01
Medical history: neoplasms
Haematological neoplasm 0·6% 0·7% –0·01 0·6% 0·6% 0·00
Malignant lymphoma 0·4% 0·4% –0·01 0·4% 0·4% 0·00
Malignant neoplasm of anorectum 0·4% 0·4% –0·01 0·4% 0·4% 0·00
Malignant neoplastic disease 13·0% 15·3% –0·06 13·6% 13·6% 0·00
Malignant tumour of breast 2·0% 2·0% 0·00 2·1% 1·8% 0·02
Malignant tumour of colon 1·4% 1·5% –0·01 1·5% 1·4% 0·01
Malignant tumour of lung 0·1% 0·2% –0·01 0·1% 0·1% –0·01
Malignant tumour of urinary bladder 1·0% 1·4% –0·03 1·1% 1·1% 0·00
Primary malignant neoplasm of prostate 2·0% 2·2% –0·01 2·1% 2·2% 0·00
Medication use
Antibacterials for systemic use 17·7% 18·8% –0·03 18·0% 17·8% 0·00
Antidepressants 16·9% 18·1% –0·03 17·3% 17·0% 0·01
Antiepileptics 7·0% 8·0% –0·04 7·3% 7·2% 0·00
Anti-inflammatory and antirheumatic products 21·9% 20·9% 0·03 21·7% 21·3% 0·01
Antineoplastic agents 0·5% 0·6% –0·01 0·6% 0·5% 0·01
Antipsoriatics 0·7% 1·0% –0·04 0·7% 0·8% –0·01
Antithrombotic agents 18·2% 22·3% –0·10 19·4% 19·1% 0·01
Drugs for acid-related disorders 23·0% 28·1% –0·12 24·5% 24·0% 0·01
Drugs for obstructive airway diseases 7·0% 7·9% –0·03 7·3% 7·1% 0·00
Drugs used in diabetes 15·9% 18·2% –0·06 16·6% 16·2% 0·01
Immunosuppressants 1·3% 2·4% –0·08 1·5% 1·8% –0·02
Lipid-modifying agents 29·8% 32·9% –0·07 30·7% 30·7% 0·00
Opioids 9·2% 11·4% –0·07 9·8% 9·8% 0·00
Psycholeptics 26·5% 29·2% –0·06 27·4% 26·8% 0·01
Psychostimulants, agents used for attention 
deficit hyperactivity disorder, and nootropics
1·2% 1·4% –0·02 1·3% 1·2% 0·01
Race
American Indian or Alaska Native ·· ·· ·· ·· ·· ··
Asian ·· ·· ·· ·· ·· ··
Black or African American ·· ·· ·· ·· ·· ··
Native Hawaiian or other Pacific Islander ·· ·· ·· ·· ·· ··
White ·· ·· ·· ·· ·· ··
Other or unknown ·· ·· ·· ·· ·· ··
Ethnicity
Hispanic or Latino ·· ·· ·· ·· ·· ··
Not Hispanic or Latino ·· ·· ·· ·· ·· ··
We report the proportion of selected baseline characteristics and standardised mean difference among ACEI, ARB, CCB, and THZ users before and after 
propensity score stratification. Less extreme standard differences through stratification suggest improved balance between patient cohorts through propensity score 
adjustment. ACEI=angiotensin-converting enzyme inhibitor. ARB=angiotensin receptor blocker. CCB=calcium channel blocker. SIDIAP=Information Systems for Research in 
Primary Care. THZ=thiazide or thiazide-like diuretic.
Table 2: Baseline patient characteristics for prevalent use of ACEI or ARB (target) and CCB or THZ (comparator) monotherapy in the SIDIAP data source
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Before stratification After stratification
Target VA-OMOP 
cohort 
(n=320 450)
Comparator 
cohort 
(n=229 063)
Standardised 
mean  
difference
Target VA-OMOP 
cohort 
(n=320 450)
Comparator 
cohort 
(n=229 063)
Standardised 
mean  
difference
Age group, years
<25 ·· ·· ·· ·· ·· ··
25–29 0·2% 0·2% 0·00 0·2% 0·2% 0·00
30–34 0·8% 0·9% –0·01 0·8% 0·8% 0·00
35–39 1·9% 2·0% –0·01 2·0% 1·9% 0·01
40–44 2·7% 2·8% –0·01 2·7% 2·6% 0·01
45–49 4·6% 4·4% 0·01 4·6% 4·4% 0·01
50–54 7·2% 7·1% 0·01 7·2% 6·9% 0·01
55–59 9·5% 10·0% –0·02 9·6% 9·4% 0·01
60–64 12·0% 13·6% –0·05 12·6% 12·4% 0·00
65–69 14·5% 14·8% –0·01 14·5% 14·6% 0·00
70–74 25·2% 22·2% 0·07 23·9% 24·2% –0·01
75–79 10·4% 9·5% 0·03 10·1% 10·4% –0·01
80–84 5·2% 5·1% 0·00 5·2% 5·4% –0·01
85–89 3·9% 4·4% –0·03 4·2% 4·3% –0·01
90–94 1·5% 2·1% –0·04 1·8% 1·9% –0·01
≥95 0·4% 0·7% –0·04 0·5% 0·6% 0·00
Sex
Female 5·2% 9·0% –0·15 6·4% 6·8% –0·02
Male 94·8% 91·0% –0·15 93·6% 93·2% –0·02
Medical history: general
Acute respiratory disease 4·3% 5·0% –0·04 4·6% 4·6% 0·00
Attention deficit hyperactivity disorder 0·7% 0·6% 0·02 0·7% 0·7% 0·00
Chronic liver disease 1·6% 2·5% –0·06 1·9% 2·0% –0·01
Chronic obstructive lung disease 7·7% 9·3% –0·06 8·4% 8·6% –0·01
Crohn’s disease 0·2% 0·2% –0·01 0·2% 0·2% 0·00
Dementia 2·0% 2·4% –0·03 2·2% 2·3% 0·00
Depressive disorder 16·7% 17·7% –0·03 17·1% 17·0% 0·00
Diabetes 37·8% 16·3% 0·50 29·5% 28·3% 0·03
Gastro-oesophageal reflux disease 13·9% 14·2% –0·01 14·1% 14·3% –0·01
Gastrointestinal haemorrhage 0·6% 0·8% –0·02 0·7% 0·8% –0·01
HIV infection 0·5% 0·8% –0·03 0·6% 0·6% 0·00
Hyperlipidaemia 48·2% 39·6% 0·17 44·7% 44·2% 0·01
Hypertensive disorder 68·4% 71·1% –0·06 69·4% 70·0% –0·01
Lesion of liver 1·2% 1·6% –0·03 1·3% 1·4% –0·01
Obesity 12·7% 10·6% 0·06 11·9% 11·6% 0·01
Osteoarthritis 14·5% 15·8% –0·04 15·0% 15·1% 0·00
Pneumonia 0·7% 0·9% –0·03 0·8% 0·8% –0·01
Psoriasis 1·2% 1·0% 0·02 1·1% 1·1% 0·00
Renal impairment 6·1% 7·1% –0·04 6·7% 7·0% –0·01
Rheumatoid arthritis 0·7% 0·8% 0·00 0·8% 0·7% 0·00
Schizophrenia 0·8% 1·2% –0·03 1·0% 1·0% –0·01
Ulcerative colitis 0·3% 0·3% 0·00 0·3% 0·3% 0·00
Urinary tract infectious disease 1·3% 1·5% –0·02 1·4% 1·4% 0·00
Viral hepatitis C 1·0% 2·0% –0·08 1·3% 1·5% –0·01
Visual system disorder 28·5% 27·7% 0·02 28·2% 28·1% 0·00
Atrial fibrillation 2·8% 2·3% 0·04 2·7% 2·8% –0·01
Cerebrovascular disease 2·3% 2·3% 0·00 2·3% 2·5% –0·01
Coronary arteriosclerosis 6·4% 4·4% 0·09 5·8% 5·8% 0·00
(Table 3 continues on next page)
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Before stratification After stratification
Target VA-OMOP 
cohort 
(n=320 450)
Comparator 
cohort 
(n=229 063)
Standardised 
mean  
difference
Target VA-OMOP 
cohort 
(n=320 450)
Comparator 
cohort 
(n=229 063)
Standardised 
mean  
difference
(Continued from previous page)
Heart disease 14·0% 11·9% 0·06 13·3% 13·6% –0·01
Heart failure 1·1% 0·8% 0·03 1·0% 0·9% 0·01
Ischaemic heart disease 1·9% 1·5% 0·03 1·7% 1·8% 0·00
Peripheral vascular disease 2·7% 2·5% 0·01 2·7% 2·7% 0·00
Pulmonary embolism 0·4% 0·4% 0·00 0·4% 0·4% 0·00
Venous thrombosis 0·8% 0·9% –0·02 0·8% 0·9% 0·00
Medical history: neoplasms
Haematological neoplasm 1·0% 1·2% –0·02 1·1% 1·1% 0·00
Malignant lymphoma 0·6% 0·6% 0·00 0·6% 0·6% 0·00
Malignant neoplasm of anorectum 0·1% 0·1% 0·00 0·1% 0·1% 0·00
Malignant neoplastic disease 7·9% 9·7% –0·06 8·6% 8·9% –0·01
Malignant tumour of breast 0·1% 0·1% –0·01 0·1% 0·1% 0·00
Malignant tumour of colon 0·3% 0·4% –0·01 0·3% 0·3% 0·00
Malignant tumour of lung 0·3% 0·5% –0·03 0·4% 0·4% 0·00
Malignant tumour of urinary bladder ·· ·· ·· ·· ·· ··
Primary malignant neoplasm of prostate 3·0% 4·1% –0·06 3·4% 3·5% –0·01
Medication use
Antibacterials for systemic use 15·6% 17·6% –0·05 16·3% 16·6% –0·01
Antidepressants 31·8% 31·6% 0·00 31·8% 31·8% 0·00
Antiepileptics 22·8% 21·2% 0·04 22·3% 22·3% 0·00
Anti-inflammatory and antirheumatic products 29·8% 33·3% –0·07 31·1% 31·2% 0·00
Antineoplastic agents 2·5% 2·9% –0·02 2·6% 2·7% 0·00
Antipsoriatics 0·6% 0·8% –0·02 0·7% 0·7% 0·00
Antithrombotic agents ·· ·· ·· ·· ·· ··
Drugs for acid-related disorders 34·2% 33·8% 0·01 34·0% 34·6% –0·01
Drugs for obstructive airway diseases 26·1% 28·7% –0·06 27·1% 27·5% –0·01
Drugs used in diabetes 39·4% 14·8% 0·58 29·6% 28·5% 0·02
Immunosuppressants 2·6% 2·9% –0·02 2·8% 2·8% 0·00
Lipid-modifying agents 64·8% 50·4% 0·30 58·9% 58·1% 0·02
Opioids 9·2% 9·8% –0·02 9·5% 9·6% –0·01
Psycholeptics 19·0% 20·6% –0·04 19·7% 19·9% –0·01
Psychostimulants, agents used for attention deficit 
hyperactivity disorder, and nootropics
1·4% 1·4% 0·01 1·4% 1·4% 0·00
Race
American Indian or Alaska Native 0·9% 0·6% 0·03 0·7% 0·7% 0·00
Asian 1·2% 0·8% 0·04 1·1% 1·1% 0·00
Black or African American 12·9% 33·5% –0·50 21·1% 21·3% 0·00
Native Hawaiian or other Pacific Islander 1·0% 0·8% 0·03 0·9% 0·9% 0·00
White 77·5% 58·6% 0·41 70·0% 69·9% 0·00
Other or unknown 6·6% 5·7% 0·03 6·2% 6·2% 0·00
Ethnicity
Hispanic or Latino 7·6% 5·2% 0·10 6·7% 6·5% 0·01
Not Hispanic or Latino 89·7% 92·4% –0·09 90·8% 90·9% 0·00
We report the proportion of selected baseline characteristics and standardised mean difference among ACEI, ARB, CCB, and THZ users before and after propensity 
score stratification. Less extreme standard differences through stratification suggest improved balance between patient cohorts through propensity score adjustment. 
ACEI=angiotensin-converting enzyme inhibitor. ARB=angiotensin receptor blocker. CCB=calcium channel blocker. THZ=thiazide or thiazide-like diuretic. VA-OMOP=US 
Department of Veterans Affairs Observational Medical Outcomes Partnership.
Table 3: Baseline patient characteristics for prevalent use of ACEI or ARB (target) and CCB or THZ (comparator) monotherapy in the VA-OMOP data source
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Before stratification After stratification
Target CUIMC 
cohort 
(n=5539)
Comparator 
CIUMC cohort 
(n=5849)
Standardised 
mean  
difference
Target CUIMC 
cohort 
(n=5539)
Comparator 
CIUMC cohort 
(n=5849)
Standardised 
mean  
difference
Age group, years
<25 0·6% 0·5% 0·01 0·7% 0·4% 0·04
25–29 0·7% 1·1% –0·04 0·8% 0·8% 0·00
30–34 1·1% 1·5% –0·03 1·3% 1·2% 0·01
35–39 1·8% 2·3% –0·04 2·0% 1·9% 0·01
40–44 2·8% 3·5% –0·04 2·8% 3·1% –0·02
45–49 4·7% 5·3% –0·03 5·1% 4·9% 0·01
50–54 7·1% 7·0% 0·00 7·3% 6·6% 0·03
55–59 9·9% 9·0% 0·03 9·7% 9·2% 0·02
60–64 13·1% 11·4% 0·05 12·5% 12·3% 0·01
65–69 14·9% 13·4% 0·04 14·4% 13·7% 0·02
70–74 15·4% 15·0% 0·01 15·1% 15·8% –0·02
75–79 11·8% 11·9% 0·00 11·8% 12·4% –0·02
80–84 8·3% 8·4% 0·00 8·1% 8·6% –0·02
85–89 4·7% 5·5% –0·03 5·0% 5·3% –0·01
90–94 2·0% 3·0% –0·06 2·3% 2·7% –0·03
≥95 0·8% 0·8% 0·00 1·0% 0·8% 0·02
Sex
Female 50·1% 58·7% –0·17 55·2% 53·9% 0·03
Male 49·9% 41·3% –0·17 44·8% 46·1% 0·03
Medical history: general
Acute respiratory disease 3·6% 4·0% –0·02 3·8% 3·8% 0·00
Attention deficit hyperactivity disorder 0·2% 0·2% –0·02 0·2% 0·2% –0·01
Chronic liver disease 0·7% 1·2% –0·05 0·7% 1·0% –0·04
Chronic obstructive lung disease 2·7% 3·1% –0·02 2·9% 2·8% 0·00
Crohn’s disease 0·3% 0·2% 0·01 0·3% 0·2% 0·03
Dementia 1·7% 2·3% –0·04 1·9% 2·1% –0·02
Depressive disorder 4·9% 6·0% –0·05 5·6% 5·5% 0·01
Diabetes 21·5% 13·2% 0·22 16·7% 17·0% –0·01
Gastro-oesophageal reflux disease 7·1% 7·1% 0·00 7·3% 6·8% 0·02
Gastrointestinal haemorrhage 0·8% 1·1% –0·03 0·8% 0·8% 0·00
HIV infection 1·9% 1·7% 0·02 2·1% 1·5% 0·05
Hyperlipidaemia 38·3% 33·1% 0·11 35·5% 35·6% 0·00
Hypertensive disorder 61·1% 69·0% –0·17 65·7% 64·3% 0·03
Lesion of liver 0·9% 1·5% –0·06 1·0% 1·4% –0·04
Obesity 9·2% 9·8% –0·02 9·3% 9·7% –0·01
Osteoarthritis 10·9% 12·2% –0·04 11·8% 11·8% 0·00
Pneumonia 1·1% 1·9% –0·06 1·2% 1·6% –0·03
Psoriasis 0·7% 0·5% 0·03 0·6% 0·5% 0·02
Renal impairment 6·5% 9·7% –0·12 7·8% 8·4% –0·02
Rheumatoid arthritis 0·8% 0·8% 0·00 0·9% 0·8% 0·02
Schizophrenia 0·2% 0·3% –0·02 0·2% 0·2% 0·00
Ulcerative colitis 0·2% 0·1% 0·01 0·2% 0·1% 0·02
Urinary tract infectious disease 2·1% 2·8% –0·05 2·5% 2·5% 0·00
Viral hepatitis C 0·4% 0·8% –0·05 0·5% 0·7% –0·03
Visual system disorder 11·1% 10·2% 0·03 10·8% 10·2% 0·02
Atrial fibrillation 5·3% 4·6% 0·03 5·0% 4·8% 0·01
Cerebrovascular disease 5·3% 5·0% 0·01 5·2% 5·0% 0·01
Coronary arteriosclerosis 13·0% 10·7% 0·07 11·8% 12·1% –0·01
(Table 4 continues on next page)
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Target CUIMC 
cohort 
(n=5539)
Comparator 
CIUMC cohort 
(n=5849)
Standardised 
mean  
difference
Target CUIMC 
cohort 
(n=5539)
Comparator 
CIUMC cohort 
(n=5849)
Standardised 
mean  
difference
(Continued from previous page)
Heart disease 27·7% 25·0% 0·06 26·4% 26·2% 0·00
Heart failure 4·2% 2·4% 0·10 3·5% 2·8% 0·04
Ischaemic heart disease 3·4% 3·3% 0·00 3·1% 3·6% –0·03
Peripheral vascular disease 3·9% 3·2% 0·04 3·4% 3·3% 0·00
Pulmonary embolism 0·3% 0·5% –0·02 0·4% 0·4% 0·00
Venous thrombosis 0·6% 1·2% –0·06 0·7% 1·0% –0·04
Medical history: neoplasms
Haematological neoplasm 1·8% 1·8% 0·00 1·8% 1·5% 0·03
Malignant lymphoma 1·0% 1·3% –0·03 1·0% 1·2% –0·02
Malignant neoplasm of anorectum 0·2% 0·2% 0·01 0·2% 0·2% 0·01
Malignant neoplastic disease 9·5% 10·8% –0·04 9·9% 10·2% –0·01
Malignant tumour of breast 1·7% 1·7% 0·00 1·9% 1·5% 0·03
Malignant tumour of colon 0·3% 0·5% –0·04 0·3% 0·5% –0·03
Malignant tumour of lung 0·5% 0·6% –0·02 0·6% 0·6% 0·00
Malignant tumour of urinary bladder 0·5% 0·5% 0·00 0·5% 0·5% 0·01
Primary malignant neoplasm of prostate 1·5% 1·8% –0·03 1·4% 1·7% –0·03
Medication use
Antibacterials for systemic use 25·7% 27·1% –0·03 26·1% 25·7% 0·01
Antidepressants 15·2% 15·5% –0·01 15·4% 15·1% 0·01
Antiepileptics 13·3% 13·0% 0·01 13·4% 12·7% 0·02
Anti-inflammatory and antirheumatic products 17·1% 20·5% –0·09 18·6% 18·9% –0·01
Antineoplastic agents 3·2% 4·1% –0·05 3·6% 3·6% 0·00
Antipsoriatics 0·6% 1·3% –0·08 0·7% 1·1% –0·04
Antithrombotic agents 21·9% 22·5% –0·02 21·7% 22·0% –0·01
Drugs for acid-related disorders 22·6% 26·9% –0·10 24·3% 24·9% –0·01
Drugs for obstructive airway diseases 14·0% 15·1% –0·03 14·5% 14·3% 0·00
Drugs used in diabetes 22·7% 12·8% 0·26 17·0% 17·8% –0·02
Immunosuppressants 5·4% 7·7% –0·09 6·6% 6·3% 0·01
Lipid-modifying agents 43·2% 35·0% 0·17 38·4% 39·4% –0·02
Opioids 10·3% 14·4% –0·12 11·6% 12·6% –0·03
Psycholeptics 14·3% 15·9% –0·05 15·1% 15·1% 0·00
Psychostimulants, agents used for attention deficit 
hyperactivity disorder, and nootropics
1·5% 1·5% 0·00 1·5% 1·5% 0·00
Race
American Indian or Alaska Native 0·2% <0·1% 0·04 0·2% <0·1% 0·04
Asian 2·3% 2·1% 0·02 2·3% 2·2% 0·02
Black or African American 5·9% 10·8% –0·18 8·3% 8·3% 0·00
Native Hawaiian or other Pacific Islander 0·8% 0·6% 0·02 0·9% 0·5% 0·04
White 36·4% 31·0% 0·11 33·3% 33·9% –0·01
Other or unknown 2·1% 2·3% –0·03 2·0% 2·3% –0·02
Ethnicity
Hispanic or Latino 11·5% 13·9% –0·07 12·6% 13·1% –0·01
Not Hispanic or Latino 35·3% 34·4% 0·02 34·3% 35·2% –0·02
We report the proportion of selected baseline characteristics and standardised mean difference among ACEI, ARB, CCB, and THZ users before and after propensity score 
stratification. Less extreme standard differences through stratification suggest improved balance between patient cohorts through propensity score adjustment. 
ACEI=angiotensin-converting enzyme inhibitor. ARB=angiotensin receptor blocker. CCB=calcium channel blocker. CUIMC=Columbia University Irving Medical Center data 
warehouse. THZ=thiazide or thiazide-like diuretic.
Table 4: Baseline patient characteristics for prevalent use of ACEI or ARB (target) and CCB or THZ (comparator) monotherapy in the CUIMC data source
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compared with CCB or THZ monotherapy users for all 
data sources are plotted in figure 2. In CUIMC, all but 
one drug comparison (ACEI vs ARB monotherapy) with 
propensity score stratification showed residual cohort 
imbalances, with a standardised mean difference of 0·1 or 
more, which involved baseline characteristics related to 
pregnancy, renal transplantation, and heart failure and 
use of sacubitril. However, these cohort comparisons all 
passed study diagnostics for the propensity score 
matching design. The appendix (pp 163–282) shows study 
diagnostics for all comparisons and includes negative 
control effect estimate distributions. The number of 
negative control outcomes analysed ranged from 33 to 80 
in CUIMC, 49 to 65 in SIDIAP, and 99 to 105 in VA-OMOP 
(appendix pp 314–17).
Calibrated HRs for the relative risk of incident 
COVID-19 diagnosis are presented in table 3 and figure 3 
for propensity score-stratified and propensity score-
matched analyses. In SIDIAP, there were 37 796 mono -
therapy and 45 239 combination users of ACEIs or ARBs. 
Compared with use of CCBs, the risk of COVID-19 
diagnosis with propensity score stratification was not 
significantly different (HR 1·02, 95% CI 0·86–1·21, with 
monotherapy and 1·06, 0·92–1·24, with combination 
use). In VA-OMOP, there were 320 450 monotherapy and 
656 274 combination users of ACEIs or ARBs. Compared 
with CCB or THZ use in VA-OMOP, the risk of COVID-19 
diagnosis was not significantly different (HR 0·91, 
95% CI 0·71–1·17, with monotherapy and 0·98, 
0·81–1·18, with combination use). Propensity score 
stratification in CUIMC with 5539 monotherapy users 
and 10 286 combinations users of ACEI or ARB did not 
pass study diagnostics. The corresponding HRs for 
CUIMC using propensity score matching were 0·67 
(95% CI 0·20–2·20) with monotherapy and 2·36 
(0·98–5·68) with combination use. Meta-analytic HRs 
following propensity score stratification for ACEI or ARB 
use compared with CCB or THZ use were 0·98 (95% CI 
0·84–1·14) for monotherapy and 1·01 (0·90–1·15) with 
combination use (table 5).
When comparing ACEI and ARB use separately to CCB 
or THZ use, we observed no significant difference with 
COVID-19 diagnosis for comparisons passing study 
diagnostics (table 3). For ACEI use, meta-analytic HRs 
following propensity score stratification were 0·91 (95% CI 
0·68–1·21) for monotherapy (but with hetero geneity of 
more than 40%) and 0·95 (0·83–1·07) for combination 
use. For ARB use, meta-analytic HRs following propensity 
score stratification were 1·10 (95% CI 0·89–1·35) with 
monotherapy and 1·08 (0·89–1·31) with combination use.
When comparing ACEI use directly with ARB use, no 
significant difference in the risk of COVID-19 diagnosis 
was observed in individual databases, apart from 
combination use in VA-OMOP (HR 0·84, 95% CI 
0·71–0·99). Meta-analytic HRs following propensity score 
stratification were 0·85 (95% CI 0·69–1·05) with 
monotherapy and 0·88 (0·79–0·99) for combination use. 
Propensity score matching, where comparisons from 
CUIMC passed all propensity score diagnostics, produced 
similar results (table 5).
Figure 2: Cohort balance diagnostics comparing ACEI or ARB and CCB or THZ monotherapy prevalent use for the risk of COVID-19 diagnosis
 We plotted the absolute standardised difference in population proportions of all available patient characteristics (6571 in SIDIAP, 11 183 in VA-OMOP, and 18 291 in 
CUIMC) before and after propensity score stratification or matching across data sources. Using stratification, CUIMC fails study diagnostics for this comparison as the 
absolute standardised mean difference is not consistently less than 0·1. Dashed lines indicate no before and after adjustment. ACEI=angiotensin-converting 
enzyme inhibitor. ARB=angiotensin receptor blocker. CCB=calcium channel blocker. CUIMC=Columbia University Irving Medical Center data warehouse. 
SIDIAP=Information Systems for Research in Primary Care. THZ=thiazide or thiazide-like diuretic. VA-OMOP=US Department of Veterans Affairs Observational 
Medical Outcomes Partnership.
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Figure 3: Calibrated HRs for 
COVID-19-related outcomes 
for ACEI, ARB, CCB, and THZ 
prevalent use across data 
sources
Outcomes are COVID-19 
diagnosis, hospital admission 
with COVID-19, hospital 
admission with pneumonia, 
and hospital admission with 
pneumonia, acute respiratory 
distress syndrome, acute 
kidney injury, or sepsis. We 
plot calibrated HRs and their 
95% CIs (indicated by error 
bars) labelled by propensity 
score adjustment method. 
Greyed out data source entries 
do not pass study diagnostics 
and greyed out meta-analysis 
entries return a heterogeneity 
(I²) value of more than 40%. 
ACEI=angiotensin-
converting enzyme inhibitor. 
ARB=angiotensin receptor 
blocker. CCB=calcium 
channel blocker. 
CUIMC=Columbia University 
Irving Medical Center data 
warehouse. HR=hazard ratio. 
SIDIAP=Information Systems 
for Research in Primary Care. 
THZ=thiazide or thiazide-like 
diuretic. VA-OMOP=US 
Department of Veterans 
Affairs Observational Medical 
Outcomes Partnership.
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Calibrated HRs for the risk of hospital admission with 
COVID-19 are presented in figure 3. We observed no 
significant association between incident hospital 
admission with COVID-19 for the comparison with ACEI 
or ARB use, evaluated either together or separately, 
compared with CCB or THZ use. For ACEI use compared 
with ARB use, using propensity score stratification, meta-
analytic HRs were 0·88 (95% CI 0·66–1·17) for 
monotherapy and 0·93 (0·82–1·07) with combination use.
No significant associations with the risk of pneumonia 
were observed with any drug comparison that satisfied 
study diagnostics. No significant associations with the 
risk of hospital admission with pneumonia, acute 
respiratory distress syndrome, acute kidney injury, or 
sepsis were observed with any drug comparison that 
satisfied study diagnostics in SIDIAP and CUIMC. In 
VA-OMOP, no significant difference was observed in 
comparisons between ARB versus CCB or THZ use 
(HR 1·09, 95% CI 0·90–1·32) or ACEI versus ARB 
use (1·02, 0·85–1·21) and the risk of hospital admission 
with pneumonia, acute respiratory distress syndrome, 
acute kidney injury, or sepsis, although small significant 
associations were observed with ACEI versus CCB or 
THZ (1·17, 1·01–1·36; appendix p 290).
Discussion
In this multicentre cohort study following more than 
1·3 million patients with hypertension from the USA and 
Spain, we observed no clear association of increased risk 
of COVID-19 diagnosis, hospital admission, or subsequent 
complications associated with the outpatient prevalent 
ACEI or ARB use. Our findings support recent regulatory 
and clinical society recommendations that patients should 
not halt their ACEI or ARB therapy despite previously 
posited mechanisms of increased COVID-19 risk.16
Studies assessing the risk of COVID-19 among ACEI 
or ARB users have been published from Italy, Spain, the 
UK, and the USA.37–42 After adjustment for the higher 
prevalence of cardiovascular conditions in patients with 
COVID-19, ACEI and ARB use was not associated with 
an increased risk of COVID-19 diagnosis. These case-
control studies included only a limited number of 
covariates for model adjustment. We identified only 
two studies that compared the risk of COVID-19 
susceptibility in ACEI or ARB users with an active 
comparator.41,42 In this context, comparing patients with 
similarly indicated treatments is crucial for reducing the 
risk of bias resulting from confounding by indication 
(eg, hypertension), in which the absence of treatment 
indicates either too mild a disease to warrant pharmaco-
logical treatment (eg, mild hypertension under control 
with lifestyle and diet changes), the presence of 
contraindications, or extreme frailty precluding the use 
of preventive medicines (eg, at the end of life).43–46 Indeed, 
de Abajo and colleagues clearly demonstrate that 
compared with other antihypertensive medication use, 
non-use was associated with a significantly reduced risk 
Propensity score stratified Propensity score matched
Calibrated HR 
(95% CI)
Calibrated 
p value
Calibrated HR 
(95% CI)
Calibrated 
p value
ACEIs or ARBs vs CCBs or THZs
Monotherapy
SIDIAP 1·02 (0·86–1·21) 0·76 1·16 (0·93–1·44) 0·24
VA-OMOP 0·91 (0·71–1·17) 0·48 1·06 (0·76–1·46) 0·74
CUIMC 1·46 (0·81–2·62)* 0·22* 0·67 (0·20–2·20) 0·53
Meta-analysis 0·98 (0·84–1·14) 0·76 1·10 (0·92–1·32) 0·31
Combination use
SIDIAP 1·06 (0·92–1·24) 0·47 1·02 (0·85–1·23) 0·76
VA-OMOP 0·98 (0·81–1·18) 0·80 1·03 (0·83–1·29) 0·77
CUIMC 1·28 (0·86–1·90)* 0·27* 2·36 (0·98–5·68) 0·06
Meta-analysis 1·01 (0·90–1·15) 0·81 1·09 (0·84–1·41)† 0·54†
ACEIs vs CCBs or THZs
Monotherapy
SIDIAP 1·05 (0·88–1·25) 0·68 1·14 (0·90–1·43) 0·34
VA-OMOP 0·77 (0·57–1·03) 0·07 1·00 (0·70–1·44) 0·96
CUIMC 0·90 (0·40–2·00)* 0·79* 0·92 (0·24–3·48) 0·86
Meta-analysis 0·91 (0·68–1·21)† 0·51† 1·08 (0·89–1·31) 0·45
Combination use
SIDIAP 0·98 (0·86–1·12) 0·75 0·95 (0·79–1·15) 0·66
VA-OMOP 0·91 (0·75–1·10) 0·33 0·87 (0·70–1·08) 0·21
CUIMC 0·65 (0·38–1·12)* 0·14* 0·45 (0·17–1·18) 0·11
Meta-analysis 0·95 (0·83–1·07) 0·38 0·88 (0·75–1·04) 0·14
ARBs vs CCBs or THZs
Monotherapy
SIDIAP 1·01 (0·79–1·30) 0·76 0·98 (0·69–1·39) 0·81
VA-OMOP 1·11 (0·78–1·58) 0·57 1·18 (0·80–1·76) 0·41
CUIMC 1·72 (0·87–3·40)* 0·13* 2·25 (0·43–11·6) 0·34
Meta-analysis 1·10 (0·89–1·35) 0·40 1·16 (0·89–1·50) 0·28
Combination use
SIDIAP 1·08 (0·89–1·31) 0·47 1·06 (0·84–1·33) 0·65
VA-OMOP 1·21 (0·99–1·49)* 0·07* 1·17 (0·93–1·47) 0·19
CUIMC 1·69 (1·12–2·55)* 0·02* 1·31 (0·61–2·85) 0·51
Meta-analysis 1·08 (0·89–1·31) 0·49 1·16 (0·99–1·36) 0·08
ACEIs vs ARBs
Monotherapy
SIDIAP 1·05 (0·83–1·33) 0·70 1·01 (0·77–1·32) 0·79
VA-OMOP 0·73 (0·51–1·04) 0·09 0·75 (0·52–1·10) 0·15
CUIMC 0·61 (0·27–1·38) 0·25 0·22 (0·02–2·63)* 0·24*
Meta-analysis 0·85 (0·69–1·05) 0·14 0·86 (0·69–1·07) 0·18
Combination use
SIDIAP 0·93 (0·79–1·10) 0·46 0·95 (0·74–1·22) 0·67
VA-OMOP 0·84 (0·71–0·99) 0·04 0·85 (0·71–1·02) 0·08
CUIMC 0·58 (0·38–0·87)* 0·01* 0·54 (0·21–1·36) 0·20
Meta-analysis 0·88 (0·79–0·99) 0·03 0·87 (0·77–0·99) 0·04
ACEI=angiotensin-converting enzyme inhibitor. ARB=angiotensin receptor blocker. CCB=calcium channel 
blocker. CUIMC=Columbia University Irving Medical Center data warehouse. HR=hazard ratio. 
SIDIAP=Information Systems for Research in Primary Care. THZ=thiazide or thiazide-like diuretic. VA-OMOP=US 
Department of Veterans Affairs Observational Medical Outcomes Partnership. *Data source entries do not pass 
study diagnostics and not included in the meta-analytic estimate. †Entries return heterogeneity (I²) values of 
more than 40%. 
Table 5: Risk of COVID-19 diagnosis among users of ACEIs, ARBs, CCBs, and THZs 
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of being admitted to hospital with COVID-19, with an 
estimated odds ratio of 0·48 (95% CI 0·34–0·69) for 
severe cases and 0·57 (0·43–0·75) for less severe cases.41
We observed one nominally significant meta-analysis 
difference: users of ACEI combination therapy had a lower 
risk of COVID-19 diagnosis when compared with users of 
ARB combination therapy. There was, however, no 
corresponding difference detected in hospital admission 
or complications. Therefore, the observed association 
might be due to chance or residual bias. Even if true, there 
is only a 12% difference, and therefore favouring ACEIs 
over ARBs for mitigating COVID-19 is not strongly 
supported by our result. There is limited evidence directly 
comparing the risk of COVID-19 between ACEI and ARB 
use. Several studies have reported main effect odds ratios 
lower than 1 with ACEIs compared with ARBs, ranging from 
0·61 (95% CI 0·41–0·93) to 0·92 (0·64–1·32) for ACEIs 
and 0·88 (0·61–1·26) to 1·10 (0·88–1·37) for ARBs.38,41–43 
However, not all observational studies have suggested a 
differential effect between ACEI and ARB use.39 Notably, 
one study comparing 124 ACEI users admitted to hospital 
with COVID-19 matched to 248 ARB users found no 
difference in the risk of 28-day all-cause mortality.47
Animal models suggest that although ACEIs increase 
ACE2 gene expression, they do not alter ACE2 activity, 
unlike ARBs, providing a potential mechanism for why 
differential effects might occur.7,48 However, recent 
studies in humans have identified no difference in 
ACE2 levels following exposure to ACEI or ARB use.49–51 
Therefore, our findings could also be explained by 
residual confounding, as suggested by recent com-
parisons of the incidence of Staphylococcus aureus 
infection and other outcomes between ACEI and ARB 
use, which suggest that ARB use is not a perfect 
comparator for ACEI use, although no large-scale 
propensity score adjustment was used.52
Furthermore, one study has reported an increased risk 
of hospital admission with COVID-19 and intensive care 
unit admission associated with use of ACEIs and ARBs.43 
Although we did not observe a consistent increased risk 
of hospital admission with COVID-19, we did observe an 
increased risk of hospital admission with pneumonia, 
acute respiratory distress syndrome, acute kidney injury, 
or sepsis largely driven by ACEI use compared with CCB 
or THZ use. This finding might be related to the higher 
incidence of acute kidney injury associated with ACEI 
use because no increased risk was observed for pneu-
monia, and acute kidney injury would be considerably 
more frequent than acute respiratory distress syndrome 
or sepsis.
We used an open science approach to apply analyses 
across a network of observational databases so results 
can be directly compared and interpreted in aggregate. 
For these analyses, we used active comparators to reduce 
confounding by indication and, for the first time in such 
a study, applied large-scale propensity adjustment with 
full diagnostics and did a large set of negative control 
experiments. We published the study protocol ahead of 
time and kept results blinded when assessing propensity 
score diagnostics, helping to address concerns about 
reproducibility, robustness, and transparency that have 
emerged.53 Our study has also been recognised by the 
European Medicines Agency ENCePP Guide on 
Methodological Standards in Pharmacoepidemiology for 
COVID-19 studies.54
We examined outpatient prevalent use of anti hyper-
tensive therapy because a new-user design in the context of 
COVID-19, which has widely affected the provision of 
routine care, is infeasible. Therefore, mediators on the 
causal pathway between exposure and outcome might be 
included in the adjustment. However, this might not 
necessarily result in bias, as COVID-19 is a new illness and 
will not have affected the decision to initiate one drug over 
another. Similarly, biological mechanisms relating to ACE2 
expression might require chronic exposure, hindering a 
new-user design. Previous treatment remains highly 
correlated with many baseline features that our large-scale 
propensity model considers when balancing patients and 
can provide some protection against this potential bias.
Furthermore, we defined COVID-19 diagnosis through 
the presence of diagnostic codes or positive test results 
that will underestimate the number of true COVID-19 
cases, the extent of which will vary by site due to 
differences in testing strategies. To address this potential 
limitation, we included a hospital admission-based 
COVID-19 outcome and observed similar results. 
Differences in the incidence of outcomes were noted 
between data sources, with VA-OMOP having much 
lower incidence than SIDIAP and CUIMC. This finding 
might relate to differences in the capture of COVID-19 
diagnosis and hospital admission within each database, 
and differences in baseline community incidence. For 
example, the population in CUIMC are from 
New York City, which was the epicentre for US cases 
during the conduct of the study. Finally, although 
exposure is based on prescription information, we cannot 
determine whether the patient ingested their medication. 
Nevertheless, these data are representative of how 
patients use such medications in the real world. Although 
we have used a rigorous approach to observational 
research,33 residual confounding is still possible.
Our findings stand in agreement with regulatory and 
clinical society advice that ACEI and ARB therapy should 
be continued in light of COVID-19. Furthermore, the 
marginal difference between ACEIs and ARBs does 
not warrant class switching to reduce COVID-19 
susceptibility.
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